Eleva administers first dose of its Factor H biological treatment in C3-Glomerulopathy to healthy volunteers
Eleva administers first dose of its Factor H biological [...]
Eleva Appoints Donato Spota as Chief Financial Officer
Eleva Appoints Donato Spota as Chief Financial Officer [...]
Eleva publishes evidence in preclinical dry AMD study
Eleva publishes evidence of immunomodulation and neuroprotection using its Factor [...]
Eleva Appoints Martin Bauer, MD as Chief Medical Officer
Eleva Appoints Martin Bauer, MD as Chief Medical Officer Adding [...]
Eleva and 3PBIOVIAN sign strategic alliance
Eleva and 3PBIOVIAN sign strategic GMP manufacturing and technology alliance [...]
Eleva appoints Dr. Elisabeth Lackner to its Supervisory Board
Eleva appoints Dr. Elisabeth Lackner to its Supervisory Board [...]
The New Role(s) of CDMOs In Biopharmaceutical Development
The New Role(s) of CDMOs In Biopharmaceutical Development [...]
Euro Health Leaders features Eleva and CEO Björn Cochlovius
Euro Health Leaders features Eleva and CEO Björn Cochlovius [...]
Eleva Receives Orphan Drug Designation in Europe for Proprietary Factor H Therapy in C3 Glomerulopathy (C3G)
Eleva receives Orphan Drug Designation in Europe for proprietary [...]
Eleva publishes preclinical data on proprietary Factor H therapy
Eleva publishes preclinical data on proprietary Factor H therapy [...]
